Catechol-O-methyltransferase val158met genotype modulates sustained attention in both the drug-free state and in response to amphetamine

Abstract

Objective: Variation in the catechol-O-methyltransferase (COMT) val(158)met polymorphism has been associated with executive cognition and working memory, presumably mediated by the prefrontal cortex. Here, we extend these observations by examining two measures of cognitive function, lapses in attention and visuo-spatial-motor speed of processing, in both the drug-free state and after administration of d-amphetamine.

Methods: Healthy Caucasian male and female participants (n=161) participated in a double-blind, crossover design study where they received placebo or d-amphetamine (10 and 20 mg). The outcome measures included self-reported mood states, a simple reaction time task, and a task measuring visuo-spatial-motor speed of processing. We first evaluated whether the genotypic groups differed on any of the measures in the absence of drug administration, including a measure of personality. We then determined whether the genotypic groups differed in their responses to acute doses of d-amphetamine (10 or 20 mg).

Results: We found that without drug, val/val and val/met carriers showed greater lapses in attention on the reaction time task than met/met carriers, but the genotypic groups did not differ on the visuo-spatial-motor speed of processing task. Val/val carriers scored higher on a personality measure of extraversion than val/met and met/met carriers. Compared with placebo, the lower dose of d-amphetamine (10 mg) improved lapses in attention and visuo-spatial-motor speed of processing in val/val carriers, and decreased lapses in attention in val/met carriers. The highest dose of d-amphetamine (20 mg) improved performance on lapses in attention and visuo-spatial-motor speed of processing tasks in both val/val and val/met carriers, but not in met/met carriers. None of the genotypic groups differed on mood states, either with or without drug administration.

Conclusion: The results of this study extend earlier findings with the COMT genotypes to additional measures of cognition, and suggest that the presence of the val allele is associated with poorer performance and greater improvement with a stimulant drug. The results further suggest that this polymorphism does not affect the mood-altering effects of d-amphetamine, consistent with the preferential influence of COMT in cortical regions.

Figures

Figure 1

Schematic of DevMod measuring lapses of attention. This figure shows the separation of the mode and the mean when there are long reaction times or ‘lapses in attention’. It shows that long reaction times change the mean while leaving the mode relatively unaffected. The difference between the mean and the mode provides a measure of the skew, and the deviation from the mode (DevMod) is considered a measure of inattention. Text and figure printed with permission from de Wit (2009).

Figure 2

Mean Area Under the Curve±SEM of subjects' performance on the Digit Symbol Substitution Test according to COMT val158met genotype. The groups did not differ significantly on the placebo session, but d-amphetamine 10 mg (***p≤0.001) and d-amphetamine 20 mg (***p≤0.001) improved performance in the val/val carriers (N=36). D-Amphetamine (20 mg) improved performance in the val/met (N=72) carriers (**p≤0.01) whereas the drug did not change performance in the met/met carriers (N=53).

Figure 3

Mean±SEM of subjects' performance on the DevMod according to COMT val158met genotype. In the absence of any drug, val/met carriers and val/val carriers had higher DevMod in comparison to met/met carriers (#p≤0.05 for both). D-Amphetamine (10 mg and 20 mg) decreased lapses in attention in the val/val carriers (N=22; ***p≤0.001 and *p≤0.05 respectively). D-Amphetamine (10 and 20 mg) also decreased lapses in attention for val/met carriers (N=49) *p≤0.05 and **p<.01 respectively). The drug did not change DevMod performance in the met/met carriers (N=28).